ANTIOXIDANTS IN PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE

1 Holvoet P Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis 1998; 137(Suppl):S33-8.

2 Vallance P. Nitric oxide in the human cardiovascular system – SKB lecture 1997. Br J Clin Pharmacol 1998; 45:433-9.

3 Cooke JP Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48:489-509.

4 Elliot TG JR Cockroft Groop PH Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci 1993; 85:687-93.

5 Creager MA JP Cooke Mendelsohn ME Impaired vasodilation of forearm resistance vessels in hypercholestrolemic humans. J Clin Invest 1990; 86:228-34.

6 Ferro CJ Webb DJ. Endothelial dysfunction and hypertension. Drugs 1997; 53(1):30-41.

7 Celermajer DS KE Sorensen Georgakopoulos D Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88:2149-55.

8 Chin JH S Azhar Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89:10-18.

9 Diaz MN B Frei Vita JA Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408-16.

10 Maxwell SRJ Lip GYH. Free radicals and antioxidants in cardiovascular disease. Br J Clin Pharmacol 1997; 44:307-17.

11 Maxwell SR H Thomason Sandler D Antioxidant status in patients with uncomplicated insulin-dependent and noninsulin- dependent diabetes mellitus. Eur J Clin Invest 1997; 27:484-90.

12 Waring WS DJ Webb Maxwell SRJ. Uric acid as a risk factor for cardiovascular disease. Q J Med 2000; 93:707-13.

13 Valkonen MM Kuusi T. Vitamin C prevents the acute atherogenic effects of passive smoking. Free Radic Biol Med 2000; 28:428-36.

14 Heitzer T S Yla-Herttuala Luoma J Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation 1996; 93:1346-53.

15 Morrow JD B Frei Longmire AW Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332:1198-203.

16 Armstrong BK JL Mann Adelstein AM Commodity consumption and ischaemic heart disease mortality with special reference to dietary practices. J Chronic Dis 1975; 36:673-7.

17 Gey KF P Puska Jordan P Inverse correlation between vitamin E and mortality from ischaemic heart disease in crosscultural epidemiology. Am J Clin Nutr 1991; 53(1):326-34.

18 Stampfer MJ CH Hennekens Manson JE Vitamin E consumption and the risk of coronary artery disease in women. N Engl J Med 1993; 328:1444-9.

19 Rimm EB MJ Stampfer Ascherio A Vitamin E consumption and the risk of coronary artery disease in men. N Engl J Med 1993; 328:1450-6.

20Lee I-M, Cook NR, Manson JE Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the women’s health study. J Natl Cancer Inst 1999; 91:2102-6.

21 Hennekens CH JE Buring Manson JE Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145-9.

22 Christen WG JM Gaziano Design of Physicians’ Health Study II – A randomized trial of betacarotene Hennekens CH. E vitamins and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000; 10:125-34.

23 Gaziano JM JE Manson Ridker PM Beta carotene therapy for chronic stable angina. Circulation 1990; 82(III):201.

24 Rapola JM J Virtamo Ripatti S Randomised trial of á- tocopherol and â-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349:1715-20.

25 Stephens NG A Parsons Schofield PM Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.

26 Mitchinson MJ NG Stephens Parsons A Mortality in the CHAOS trial. Lancet 1999; 353:381-2.

27 Boaz M S Smetana Weinstein T Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356:1213-18.

28GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:447-55.

29The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342:154-60.

30 Jialal I S Devaraj Huet BA GISSI-Prevenzione trial (letter). Lancet 1999; 354:1554.

31 Hercberg S P Preziosi Briancon S A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: The SU.VI.MAX study – Design, methods, and participant characteristics. Control Clin Trials 1998; 19:336-51.

32 Meade T P Sleight Collins R MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999; 20:725-41.